Crossmark

A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)—based on real-world data analysis

Crossref DOI link: https://doi.org/10.1007/s11255-025-04567-2

Published Online: 2025-05-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Shaolong

Chen, Chuanjian

Mo, Chunhao

Fan, Ning

Ning, Zhongyun

Wang, Zhiping

Ding, Hui
Funding

Funding for this research was provided by:

Department of Science and Technology of Gansu Province (21JR1RA119)

Basic research of science and technology innovation application - surface project (CY2021-MS-B03)
License Information

Text and Data Mining valid from 2025-05-14

Version of Record valid from 2025-05-14
More Information

Article History

Received: 28 February 2025

Accepted: 1 May 2025

First Online: 14 May 2025

Declarations

:

: The authors declare no competing interests.

: Patient consent was waived due to this study is a retrospective study.

Document is current

Any future updates will be listed below